Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20435872 | 0.89 | HPGD (0.55) | HPGDMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20435885 | 0.83 | AKR1B1 (0.64) | HPGDMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL20435866 | 0.83 | HPGD (0.56) | HPGDMAPTLMNATSHRL3MBTL1 | |
| SCHEMBL20435858 | 0.82 | HPGD (0.55) | HPGDMAPTLMNATSHRNPC1 | |
| SCHEMBL20435870 | 0.80 | HPGD (0.58) | HPGDMAPTLMNATSHRL3MBTL1 | |
| SCHEMBL20435725 | 0.80 | HPGD (0.58) | HPGDMAPTLMNATSHRL3MBTL1 | |
| SCHEMBL30579886 | 0.79 | TDP1 (0.64) | NPC1RAB9ATDP1NPBWR1HTT | |
| SCHEMBL21033058 | 0.78 | HPGD (0.56) | HPGDMAPTLMNATSHRL3MBTL1 | |
| SCHEMBL20435747 | 0.78 | HPGD (0.61) | HPGDMAPTLMNATSHRL3MBTL1 | |
| SCHEMBL20435883 | 0.77 | HPGD (0.55) | HPGDMAPTLMNATSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | Zander Therapeutics, Inc. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | Zander Therapeutics, Inc. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019104201-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS | Zander Therapeutics, Inc. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019104199-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY | REGEN BIOPHARMA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | Zander Therapeutics, Inc. | 2019-02-21 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | HPGD 3307/4885MAPT 3849/4885LMNA 4829/4885 |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | NR4A2, NR2C2, NR0B2 | HPGD 3537/4885MAPT 4139/4885LMNA 4829/4885 |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | NR4A2, NR2C2, NR0B2 | HPGD 3537/4885MAPT 4139/4885LMNA 4829/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | HPGD 3307/4885MAPT 3849/4885LMNA 4829/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | HPGD 3275/4885MAPT 4240/4885LMNA 4840/4885 |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | NR4A2, NR2C2, NR0B2 | HPGD 3537/4885MAPT 4139/4885LMNA 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.